Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
Rhea-AI Summary
Microbot Medical (Nasdaq: MBOT) appointed Alon Tamir as Vice President of Sales for EMEA to accelerate commercial readiness for the LIBERTY Endovascular Robotic System.
The company holds FDA clearance (Sept 2025), completed a Limited and Full Market Release in the U.S., and expects a CE mark by end of 2026; Europe procedure volume is cited at ~2.3 million peripheral endovascular procedures.
Positive
- FDA clearance received in September 2025
- Completed Limited and Full Market Release phases in the U.S.
- Appointed Alon Tamir as VP Sales for EMEA
- Europe peripheral procedure volume ~2.3 million
Negative
- CE mark approval is still pending (expected by end of 2026)
- Must establish EMEA regulatory, operational, and commercial capabilities before market entry
News Market Reaction – MBOT
In the Apr 30 session, MBOT gained 2.45%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Guideline alignment | Positive | +2.8% | New protection guidelines highlighted LIBERTY’s potential radiation and ergonomics benefits. |
| Apr 14 | Conference presentation | Positive | +3.4% | Planned Needham conference presentation on FMR progress and growth strategy. |
| Apr 13 | Full market launch | Positive | -9.3% | Announcement of U.S. Full Market Release and expanded sales footprint. |
| Mar 26 | Clinical usage update | Positive | +3.6% | Emory’s first robotic PAE and Y-90 mapping cases using LIBERTY. |
| Mar 24 | Pivotal study paper | Positive | -0.8% | ACCESS-PVI pivotal study publication supporting broader LIBERTY adoption. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent commercial and clinical news has often led to positive reactions, though key launch milestones have sometimes seen negative or muted moves.
Over the past weeks, Microbot Medical has focused on commercializing its LIBERTY endovascular robotic system. On March 24, 2026, publication of the ACCESS-PVI pivotal study reinforced clinical evidence. Emory’s first robotic PAE and Y-90 cases on March 26, 2026 supported real-world adoption. In April, the company moved from Limited to Full Market Release in the U.S., expanded sales territories, and highlighted these achievements at a major healthcare conference. Updated occupational protection guidelines on April 22, 2026 further strengthened LIBERTY’s positioning. Today’s EMEA-focused commercial hire extends this commercialization narrative internationally.
Key Terms
endovascular medical
ce mark regulatory
fda clearance regulatory
mdr process regulatory
at-the-market offering financial
prospectus supplement regulatory
shelf registration statement regulatory
form s-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S.
Strong physician interest at recent Society of Interventional Radiology conference and rising awareness across markets outside the U.S. supports commercial readiness throughout heavily populated regions
HINGHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, is continuing to implement its growth strategy with the appointment of Alon Tamir as Vice President of Sales, Europe, the Middle East and Asia (EMEA). The Company will continue to prioritize its commercial efforts in the U.S. market, while establishing regulatory, operational, and commercial core capabilities required to enter international markets. The Company’s approach for EMEA will leverage the successful commercial launch of the LIBERTY system to expand into key international markets, either by utilizing its FDA clearance or through the CE mark, which is expected by the end of this year. In this capacity, Mr. Tamir will lead the development and execution of a comprehensive EMEA sales strategy, including go-to-market strategies, distribution, and strategic partnerships, new product launches tailored to market needs, and regulatory requirements across the region.
Mr. Tamir brings over two decades of experience in medical technology, with a successful track record of translating strategic vision into measurable impact. The EMEA region represents a significant growth opportunity. The Company believes Europe alone represents a peripheral endovascular procedure volume comparable to that of the United States, at approximately 2.3 million procedures, underscoring a significant opportunity for expansion beyond the U.S. market.
The Company received U.S. Food and Drug Administration (FDA) clearance for its technology in September 2025 and remains on track with its MDR process, with the anticipation of receiving a CE mark approval by the end of 2026. The Company also plans to pursue opportunities in countries where it can leverage its FDA clearance, which may help accelerate international expansion.
“Endovascular robotics is at an inflection point, and LIBERTY is leading that transformation,” commented Alon Tamir, Vice President of Sales, Europe, the Middle East and Asia (EMEA). “With over two decades of experience across the diagnostic, interventional, and robotics space, I’ve rarely seen a technology so well positioned — FDA-cleared, already commercially launched, and now advancing toward CE mark approval. The opportunity in EMEA is substantial, and I am committed to ensuring we capture it with the same discipline and execution that defined the U.S. launch.”
“As we continue to focus on the U.S. market, and build on the growing adoption of the LIBERTY System, especially after entering the Full Market Release phase, it is equally important that we establish a robust commercial readiness strategy in certain international markets, applying the same disciplined approach that supported our successful execution ahead of commencing commercialization in the U.S.,” commented Harel Gadot, Chairman, CEO and President. “Alon’s addition strengthens our ability to expand our presence in key markets outside the U.S. and advance key distribution and strategic partnerships, leveraging local expertise to ensure a well-coordinated commercial strategy ahead of regulatory approval in these markets.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
